Ipsen's Phase 3 Trial for Biliary Atresia Treatment Fails Primary Endpoint
A phase 3 clinical trial of Ipsen’s (IPSEY) drug Bylvay, used to treat biliary atresia in children, did not meet its primary endpoint. The study aimed to assess whether the medication could improve native liver survival compared to a placebo but showed no significant benefit. Bylvay is an oral therapy designed as a once-daily treatment for this rare pediatric condition affecting bile flow and leading to progressive liver damage. Despite earlier positive results in phase 2 trials, the failure of the latest trial raises questions about its efficacy at larger scales or under different conditions. The outcome could impact Ipsen’s market position within the niche pharmaceutical sector targeting rare diseases.
Topics: biliary atresia Bylvay drug development Ipsen